James Tauras, MD, provides his perspectives on issues related to the rapidly evolving pharmacologic management of chronic heart failure. Dr. Tauras emphasizes guideline-directed medical therapy as recommended in the 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, including the real-world use of ivabradine and sacubitril/valsartan. He discusses other issues intended to help improve the health outcomes, including reducing the 30-day readmission rate, of patients with heart failure.
This activity was developed for cardiologists, primary care physicians, nurse practitioners, nurses and other health care professionals who have an interest in heart failure.
1.00 AMA PRA Category 1 Credit™.
1.00 ANCC Contact Hour
|Opens:||September 30, 2017|
|Expires:||September 29, 2018|
Primary Care Physicians
Other Health Care Providers